Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026 21:59:12
Lifevantage (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
5,05 2,64 0,13 435 049
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.02.2026
Popis společnosti
Obecné informace
Název společnostiLifeVantage Corp
TickerLFVN
Kmenové akcie:Ordinary Shares
RICLFVN.O
ISIN-
Poslední známé roční výsledky30.06.2025
Poslední známé čtvrtletní výsledky31.12.2025
Počet zaměstnanců k 30.06.2025 232
Akcie v oběhu k 03.02.2026 12 793 359
MěnaUSD
Kontaktní informace
Ulice3300 TRIUMPH BLVD, SUITE 700
MěstoLEHI
PSČ84043
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 014 329 000
Fax13026365454

Business Summary: LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.
Financial Summary: BRIEF: For the six months ended 31 December 2025, LifeVantage Corp revenues decreased 16% to $96.5M. Net income decreased 44% to $2.4M. Revenues reflect Americas segment decrease of 19% to $75.7M, Asia/Pacific & Europe segment decrease of 1% to $20.8M. Net income also reflects Selling products to an international network segment income decrease of 54% to $2.8M. Dividend per share increased from $0.08 to $0.09.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSResearch and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 14.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorSteven Fife6625.10.2021
Chief Financial OfficerCarl Aure5225.10.202125.10.2021
Chief People OfficerMichelle Oborn-Virchow45
Chief Technology OfficerMike Edwards-07.01.202607.01.2026
General Counsel, Corporate SecretaryAlissa Neufeld4631.03.202131.03.2021
Chief Sales OfficerKristen Cunningham41